Citation: Liu Yu, Xun Xiao-Hong, Yi Jian-Ming, Xiang Yang, Hua Jie. Discovery of lung squamous carcinoma biomarkers by profiling the plasma peptide with LC/MS/MS[J]. Chinese Chemical Letters, ;2017, 28(5): 1093-1098. doi: 10.1016/j.cclet.2016.11.026 shu

Discovery of lung squamous carcinoma biomarkers by profiling the plasma peptide with LC/MS/MS

College of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang 414006, China

Corresponding author: Hua Jie, huajie663@163.com
Received Date: 31 July 2016
Revised Date: 14 October 2016
Accepted Date: 28 October 2016
Available Online: 27 May 2016

Figures(2)

Biomarkers can be used for the screening and clinical diagnosis of cancer, and peptidomics approach has been proven successful in the research of biomarkers. To develop better peptidomic technologies for fast, accurate, and reliable detection of peptides biomarkers for lung cancer, we have improved the procedures of blood collection to minimize the degradation of the blood proteins and optimize the extraction of peptidome peptides from plasma samples based on acetonitrile precipitation associated with size exclusion chromatography (SEC). Studies show that squamous cell carcinomas are found to express CAGE1, SPAT9 and TEX28 genes at significantly higher rates, and the results suggest that as tumors progress, the level of CAGE1, SPAT9 and TEX28 genes are likely to increase and lead to immunization. This suggests a potentially important therapeutic method for cancer testis-based cancer vaccines.
- Lung cancer,
- Lung squamous carcinoma,
- Biomarkers,
- Cancer testis antigen,
- Peptidomics
1. [1]
  C.A. Granville, P.A. Dennis. An overview of lung cancer genomics and proteomics[J]. Am. J. Respir. Cell Mol. Biol., 2005,32:169-176. doi: 10.1165/rcmb.F290
2. [2]
  H.Y. Wu, Y.G. Goan, Y.H. Chang. Qualification and verification of serological biomarker candidates for lung adenocarcinoma by targeted mass spectrometry[J]. J. Proteome Res., 2015,14:3039-3050. doi: 10.1021/pr501195t
3. [3]
  S.K. Arya, S. Bhansali. Lung cancer and its early detection using biomarkerbased biosensors[J]. Chem. Rev., 2011,111:6783-6809. doi: 10.1021/cr100420s
4. [4]
  I.E. Tothill. Biosensors for cancer markers diagnosis[J]. Semin. Cell Dev. Biol., 2009,20:55-62. doi: 10.1016/j.semcdb.2009.01.015
5. [5]
  A.K. Greenberg, M.S. Lee. Biomarkers for lung cancer:clinical uses[J]. Curr. Opin. Pulm. Med., 2007,13:249-255. doi: 10.1097/MCP.0b013e32819f8f06
6. [6]
  M.A. Alm El-Din, G. Farouk, H. Nagy, A. Abd Elzaher, G.H. Abo El-Magd. Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer[J]. Int. J. Biol. Markers, 2012,27:39-46. doi: 10.5301/JBM.2011.8738
7. [7]
  P. Tantipaiboonwong, S. Sinchaikul, S. Sriyam, S. Phutrakul, S.T. Chen. Different techniques for urinary protein analysis of normal and lung cancer patients[J]. Proteomics, 2005,5:1140-1149. doi: 10.1002/(ISSN)1615-9861
8. [8]
  H.J. Sung, J.Y. Cho. Biomarkers for the lung cancer diagnosis and their advances in proteomics[J]. BMB Rep., 2008,41:615-625. doi: 10.5483/BMBRep.2008.41.9.615
9. [9]
  C. Brambilla, F. Fievet, M. Jeanmart. Early detection of lung cancer:role of biomarkers[J]. Eur. Respir. J., 2003,39(Suppl):36s-44s.
10. [10]
  E.F. Patz Jr., M.J. Campa, E.B. Gottlin. Panel of serum biomarkers for the diagnosis of lung cancer[J]. J. Clin. Oncol., 2007,25:5578-5583. doi: 10.1200/JCO.2007.13.5392
11. [11]
  P. Verhaert, S. Uttenweiler-Joseph, M. de Vries. Matrix-assisted laser desorption/ionization quadrupole time-of-flight mass spectrometry:an elegant tool for peptidomics[J]. Proteomics, 2001,1:118-131. doi: 10.1002/(ISSN)1615-9861
12. [12]
  K. Sasaki, K. Sato, Y. Akiyama. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines[J]. Cancer Res., 2002,62:4894-4898.
13. [13]
  G. Menschaert, T.T.M. Vandekerckhove, G. Baggerman. Peptidomics coming of age:a review of contributions from a bioinformatics angle[J]. J. Proteome Res., 2010,9:2051-2061. doi: 10.1021/pr900929m
14. [14]
  M. Schrader, H. Selle. The process chain for peptidomic biomarker discovery[J]. Dis. Markers, 2006,22:27-37. doi: 10.1155/2006/174849
15. [15]
  E.F. Petricoin, C. Belluco, R.P. Araujo, L.A. Liotta. The blood peptidome:a higher dimension of information content for cancer biomarker discovery[J]. Nat. Rev. Cancer, 2006,6:961-967. doi: 10.1038/nrc2011
16. [16]
  J. Villanueva, J. Philip, L. DeNoyer, P. Tempst. Data analysis of assorted serum peptidome profiles[J]. Nat. Protoc., 2007,2:588-602. doi: 10.1038/nprot.2007.57
17. [17]
  J. Villanueva, A. Nazarian, K. Lawlor. A sequence-specific exopeptidase activity test (SSEAT) for functional biomarker discovery[J]. Mol. Cell. Proteomics, 2008,7:509-518.
18. [18]
  Z. Zhang, R.C. Bast Jr., Y.H. Yu. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer[J]. Cancer Res., 2004,64:5882-5890. doi: 10.1158/0008-5472.CAN-04-0746
19. [19]
  Y.F. Shen, T. Liu, N. Toli c. Strategy for degradomic-peptidomic analysis of human blood plasma[J]. J. Proteome Res., 2010,9:2339-2346. doi: 10.1021/pr901083m
20. [20]
  N.L. Anderson, N.G. Anderson, T.W. Pearson. A human proteome detection and quantitation project[J]. Mol. Cell. Proteomics, 2009,8:883-886. doi: 10.1074/mcp.R800015-MCP200
21. [21]
  A. Zougman, B. Pilch, A. Podtelejnikov. Integrated analysis of the cerebrospinal fluid peptidome and proteome[J]. J. Proteome Res., 2008,7:386-399. doi: 10.1021/pr070501k
22. [22]
  J. Villanueva, J. Philip, D. Entenberg. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry[J]. Anal. Chem., 2004,76:1560-1570. doi: 10.1021/ac0352171
23. [23]
  O. Chertov, A. Biragyn, L.W. Kwak. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry[J]. Proteomics, 2004,4:1195-1203. doi: 10.1002/(ISSN)1615-9861
24. [24]
  M.P.A. Ebert, D.Niemeyer , S.O. Deininger. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry[J]. J. Proteome Res., 2006,5:2152-2158. doi: 10.1021/pr060011c
25. [25]
  E. Gianazza, V. Mainini, G. Castoldi. Different expression of fibrinopeptide A and related fragments in serum of type 1 diabetic patients with nephropathy[J]. J. Proteomics, 2010,73:593-601. doi: 10.1016/j.jprot.2009.07.006
26. [26]
  F. Zito, F. Drummond, S.R. Bujac. Epidemiological and genetic associations of activated factor Ⅻ concentration with factor Ⅶ activity, fibrinopeptide A concentration, and risk of coronary heart disease in men[J]. Circulation, 2000,102:2058-2062. doi: 10.1161/01.CIR.102.17.2058
27. [27]
  K. Ueda, N. Sachiko, S. Takami. A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma[J]. PLoS One, 2011,6e18567. doi: 10.1371/journal.pone.0018567
28. [28]
  R.R. Subramanian, S.C. Masters, H.Y. Zhang, H.A. Fu. Functional conservation of 14-3-3 isoforms in inhibiting bad-induced apoptosis[J]. Exp. Cell Res., 2001,271:142-151. doi: 10.1006/excr.2001.5376
29. [29]
  S. Basu, N.F. Totty, M.S. Irwin, M. Sudol, J. Downward. Akt phosphorylates the Yes-associated protein YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis[J]. Mol. Cell, 2003,11:11-23. doi: 10.1016/S1097-2765(02)00776-1
30. [30]
  S.M. Troyanovsky, R.E. Leube, W.W. Franke. Characterization of the human gene encoding cytokeratin 17 and its expression pattern[J]. Eur. J. Cell Biol., 1992,59:127-137.
31. [31]
  C. Cataisson, R. Ohman, G. Patel. Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis[J]. Cancer Res., 2009,69:319-328. doi: 10.1158/0008-5472.CAN-08-2490
32. [32]
  M. van de Rijn, C.M. Perou, R. Tibshirani. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome[J]. Am. J. Pathol., 2002,161:1991-1996. doi: 10.1016/S0002-9440(10)64476-8
33. [33]
  M. Sarbia, F. Fritze, H. Geddert, K. Gellert. Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas:is analysis of cytokeratin 17 expression helpful[J]. Am. J. Clin. Pathol., 2007,128:255-259. doi: 10.1309/EEML5CH79PWD0R2D
34. [34]
  N. Okuyama, Y. Ide, M. Nakano. Fucosylated haptoglobin is a novel marker for pancreatic cancer:a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation[J]. Int. J. Cancer, 2006,118:2803-2808. doi: 10.1002/(ISSN)1097-0215
35. [35]
  S.J. Yoon, S.Y. Park, P.C. Pang. N-Glycosylation status of β-haptoglobin in sera of patients with prostate cancer vs benign prostate diseases[J]. Int. J. Oncol., 2010,36:193-203.
36. [36]
  A. Bharti, P.C. Ma, G. Maulik. Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer[J]. Anticancer Res., 2004,24:1031-1038.
37. [37]
  L.F.M. Hoagland, M.J. Campa, E.B. Gottlin, J.E. Herndon, E.F. Patz Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer[J]. Cancer, 2007,110:2260-2268. doi: 10.1002/(ISSN)1097-0142
38. [38]
  M. Guergova-Kuras, I. Kurucz, W. Hempel. Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries[J]. Mol. Cell. Proteomics, 2011,10:M111-010298.
39. [39]
  S. Park, Y. Lim, D. Lee. Identification and characterization of a novel cancer/testis antigen gene CAGE-1[J]. Biochim. Biophys. Acta, 2003,1625:173-182. doi: 10.1016/S0167-4781(02)00620-6
40. [40]
  Y. Liu, Y. Geng, K.Z. Li. Comparative proteomic analysis of the function and network mechanisms of MASPIN in human lung cells[J]. Exp. Ther. Med., 2012,3:470-474.
41. [41]
  L.J. Cheng, J.M. Li, J. Chen. NYD-SP16, a novel gene associated with spermatogenesis of human testis[J]. Biol. Reprod., 2003,68:190-198. doi: 10.1095/biolreprod.102.004242
42. [42]
  R. Metlapally, M. Michaelides, A. Bulusu. Evaluation of the x-linked highgrade myopia locus (MYP1) with cone dysfunction and color vision deficiencies[J]. Invest. Ophthalmol. Vis. Sci., 2009,50:1552-1558. doi: 10.1167/iovs.08-2455
43. [43]
  H. Ueyama, R. Torii, S. Tanabe, S. Oda, S. Yamade. An insertion/deletion TEX28 polymorphism and its application to analysis of red/green visual pigment gene arrays[J]. J. Hum. Genet., 2004,49:548-557. doi: 10.1007/s10038-004-0189-5
44. [44]
  O.L. Caballero, Y.T. Chen. Cancer/testis (CT) antigens:potential targets for immunotherapy[J]. Cancer Sci., 2009,100:2014-2021. doi: 10.1111/cas.2009.100.issue-11
45. [45]
  O. Hofmann, O.L. Caballero, B.J. Stevenson. Genome-wide analysis of cancer/testis gene expression[J]. Proc. Natl. Acad. Sci. U. S. A., 2008,105:20422-20427. doi: 10.1073/pnas.0810777105
46. [46]
  M.J. Scanlan, A.O. Gure, A.A. Jungbluth, L.J. Old, Y.T. Chen. Cancer/testis antigens:an expanding family of targets for cancer immunotherapy[J]. Immunol. Rev., 2002,188:22-32. doi: 10.1034/j.1600-065X.2002.18803.x
47. [47]
  A.J.W. Zendman, D.J. Ruiter, G.N.P. Van Muijen. Cancer/testis-associated genes:identification, expression profile, and putative function[J]. J. Cell. Physiol., 2003,194:272-288. doi: 10.1002/(ISSN)1097-4652
48. [48]
  B. Bodey. Cancer-testis antigens:promising targets for antigen directed antineoplastic immunotherapy[J]. Exp. Opin. Biol. Ther., 2002,2:577-584. doi: 10.1517/14712598.2.6.577
49. [49]
  Q.Y. Chen, H. Jackson, P. Parente. Immunodominant CD⁴⁺ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant[J]. Proc. Natl. Acad. Sci. U. S. A., 2004,101:9363-9368. doi: 10.1073/pnas.0403271101
50. [50]
  I.D. Davis, W.S. Chen, H. Jackson. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibodyand CD⁴⁺ and CD⁸⁺ T cell responses in humans[J]. Proc. Natl. Acad. Sci. U. S. A., 2004,101:10697-10702. doi: 10.1073/pnas.0403572101
51. [51]
  C. Lurquin, B. Lethé, E. De Plaen. Contrasting frequencies of antitumor and anti-vaccine Tcells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen[J]. J. Exp. Med., 2005,201:249-257. doi: 10.1084/jem.20041378
52. [52]
  C. Germeau, W.B. Ma, F. Schiavetti. High frequency of antitumor Tcells in the blood of melanoma patients before and after vaccination with tumor antigens[J]. J. Exp. Med., 2005,201:241-248. doi: 10.1084/jem.20041379
1. [1]
  Huamei Zhang , Jingjing Liu , Mingyue Li , Shida Ma , Xucong Zhou , Aixia Meng , Weina Han , Jin Zhou . Imaging polarity changes in pneumonia and lung cancer using a lipid droplet-targeted near-infrared fluorescent probe. Chinese Chemical Letters, 2024, 35(12): 110020-. doi: 10.1016/j.cclet.2024.110020
2. [2]
  Haiyan Lu , Jiayue Ye , Yiping Wei , Hua Zhang , Konstantin Chingin , Vladimir Frankevich , Huanwen Chen . Tracing molecular margins of lung cancer by internal extractive electrospray ionization mass spectrometry. Chinese Chemical Letters, 2025, 36(2): 110077-. doi: 10.1016/j.cclet.2024.110077
3. [3]
  Lishan Xiong , Xinyuan Li , Xiaojie Lu , Zhendong Zhang , Yan Zhang , Wen Wu , Chenhui Wang . Inhaled multilevel size-tunable, charge-reversible and mucus-traversing composite microspheres as trojan horse: Enhancing lung deposition and tumor penetration. Chinese Chemical Letters, 2024, 35(9): 109384-. doi: 10.1016/j.cclet.2023.109384
4. [4]
  Zhi Li , Shuya Pan , Yuan Tian , Shaowei Liu , Weifeng Wei , Jinlin Wang , Tianfeng Chen , Ling Wang . Selenium nanoparticles enhance the chemotherapeutic efficacy of pemetrexed against non-small cell lung cancer. Chinese Chemical Letters, 2024, 35(12): 110018-. doi: 10.1016/j.cclet.2024.110018
5. [5]
  Xiaoshuai Wu , Bailei Wang , Yichen Li , Xiaoxuan Guan , Mingjing Yin , Wenquan Lv , Yin Chen , Fei Lu , Tao Qin , Huyang Gao , Weiqian Jin , Yifu Huang , Cuiping Li , Ming Gao , Junyu Lu . NIR driven catalytic enhanced acute lung injury therapy by using polydopamine@Co nanozyme via scavenging ROS. Chinese Chemical Letters, 2025, 36(2): 110211-. doi: 10.1016/j.cclet.2024.110211
6. [6]
  Xiaoxiao Wang , Bolun Wang , Fenfen Ji , Jie Yan , Jiacheng Fang , Doudou Zhang , Ji Xu , Jing Ji , Xinran Hao , Hemi Luan , Yanjun Hong , Shulan Qiu , Min Li , Zhu Yang , Wenlan Liu , Xiaodong Cai , Zongwei Cai . Discovery of plasma biomarkers for Parkinson’s disease diagnoses based on metabolomics and lipidomics. Chinese Chemical Letters, 2024, 35(11): 109653-. doi: 10.1016/j.cclet.2024.109653
7. [7]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
8. [8]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
9. [9]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
10. [10]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110
11. [11]
  Haijing Cui , Weihao Zhu , Chuning Yue , Ming Yang , Wenzhi Ren , Aiguo Wu . Recent progress of ultrasound-responsive titanium dioxide sonosensitizers in cancer treatment. Chinese Chemical Letters, 2024, 35(10): 109727-. doi: 10.1016/j.cclet.2024.109727
12. [12]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
13. [13]
  Zhaorui Song , Qiulian Hao , Bing Li , Yuwei Yuan , Shanshan Zhang , Yongkuan Suo , Hai-Hao Han , Zhen Cheng . NIR-Ⅱ fluorescence lateral flow immunosensor based on efficient energy transfer probe for point-of-care testing of tumor biomarkers. Chinese Chemical Letters, 2025, 36(1): 109834-. doi: 10.1016/j.cclet.2024.109834
14. [14]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
15. [15]
  Huijiao Fu , Peiqin Liang , Qianwen Chen , Yan Wang , Guang Li , Xuzi Cai , Shengtao Wang , Kun Chen , Shengying Shi , Zhiqiang Yu , Xuefeng Wang . COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach. Chinese Chemical Letters, 2024, 35(8): 109241-. doi: 10.1016/j.cclet.2023.109241
16. [16]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264
17. [17]
  Xiangqian Cao , Chenkai Yang , Xiaodong Zhu , Mengxin Zhao , Yilin Yan , Zhengnan Huang , Jinming Cai , Jingming Zhuang , Shengzhou Li , Wei Li , Bing Shen . Synergistic enhancement of chemotherapy for bladder cancer by photothermal dual-sensitive nanosystem with gold nanoparticles and PNIPAM. Chinese Chemical Letters, 2024, 35(8): 109199-. doi: 10.1016/j.cclet.2023.109199
18. [18]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
19. [19]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
20. [20]
  Boran Cheng , Lei Cao , Chen Li , Fang-Yi Huo , Qian-Fang Meng , Ganglin Tong , Xuan Wu , Lin-Lin Bu , Lang Rao , Shubin Wang . Fluorine-doped carbon quantum dots with deep-red emission for hypochlorite determination and cancer cell imaging. Chinese Chemical Letters, 2024, 35(6): 108969-. doi: 10.1016/j.cclet.2023.108969

Get Citation

PDF

XML

Metrics

PDF Downloads(1)
Abstract views(627)
HTML views(5)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142